StockData
Cadrenal Therapeutics, Inc. logo

Cadrenal Therapeutics, Inc. (CVKD) stock

CVKDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 9/30
$1.88+0.48 (+34.29%)

Close on Nov 17, 2026Market cap $6.71MP/E –Yield 877.66%

Cadrenal Therapeutics EPS

Diluted earnings per share is net income divided by the share count including options and convertible securities.

Cadrenal Therapeutics's EPS for the twelve months ending Jun 30, 2026 was -$4.92. For fiscal 2025 it was -$6.64.

Annual eps

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$6.64–
FY2024Dec 31, 2024-$8.73–
FY2023Dec 31, 2023-$9.29–

Quarterly eps

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$1.14–
Q1 FY2026Mar 31, 2026-$1.04–
Q4 FY2025Dec 31, 2025-$1.43–
Q3 FY2025Sep 30, 2025-$1.31–
Q2 FY2025Jun 30, 2025-$1.87–
Q1 FY2025Mar 31, 2025-$2.09–
Q4 FY2024Dec 31, 2024-$3.57–
Q3 FY2024Sep 30, 2024-$2.18–
Q2 FY2024Jun 30, 2024-$2.24–
Q1 FY2024Mar 31, 2024-$1.56–
Q4 FY2023Dec 31, 2023-$1.07–
Q1 FY2023Mar 31, 2023-$7.20–

More Cadrenal Therapeutics figures

See a number that looks wrong?